28 results match your criteria: "and F-CRIN INI-CRCT Cardiovascular and Renal Clinical Trialists[Affiliation]"
Free Radic Res
January 2017
h Inserm, Centre d'Investigations Cliniques - Plurithématique 14-33, and Inserm U1116, CHU de Nancy, and Université de Lorraine, France and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy , France.
Statin treatment reduces the risk of cardiovascular mortality in the general population, but it has little or no benefit in hemodialyzed (HD) patients. This may reflect different underlying pathophysiology of cardiovascular disease (CVD) in patients treated with HD, maybe involving the oxidative stress. Our aim was to assess the association of oxidized low-density lipoprotein (oxLDL), determined by Mercodia oxLDL enzyme-linked immunosorbent assay (ELISA) kit, with major adverse cardiac events (MACE) and all-cause mortality in HD patients based on the AURORA trial (rosuvastatin vs placebo), and patients not on HD from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.
View Article and Find Full Text PDFPharmacol Res
April 2017
University of Michigan School of Medicine, Ann Arbor, MI, USA; Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, Inserm U1116, CHRU Nancy, Université de Lorraine, Association Lorraine de Traitement de l'Insuffisance Rénale, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. Electronic address:
Expert Opin Drug Saf
May 2016
b Inserm, Centre d'Investigations Cliniques- Plurithématique 14-33, Inserm U1116, CHU Nancy , Université de Lorraine, Association Lorraine de Traitement de l'Insuffisance Rénale, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy , France.
Introduction: Mineralocorticoid receptor antagonists (MRAs) have been accorded a class 1 indication for patients with chronic heart failure and a reduced left ventricular ejection fraction (HFREF) in both European and American guidelines. Uptake, however, has been less than optimal largely due to concerns about their safety, in particular the risk of hyperkalemia and renal dysfunction.
Areas Covered: This review presents the current state of affairs regarding the safety of MRAs in heart failure with reduced ejection fraction.
© LitMetric 2025. All rights reserved.